STATE OF NEW JERSEY
220th LEGISLATURE
PRE-FILED FOR INTRODUCTION IN THE 2022 SESSION
Sponsored by:
Assemblyman THOMAS P. GIBLIN
District 34 (Essex and Passaic)
Assemblyman DANIEL R. BENSON
District 14 (Mercer and Middlesex)
Co-Sponsored by:
Assemblyman Freiman, Assemblywoman Murphy, Assemblyman Stanley, Assemblywomen Lopez, McKnight and Assemblyman Mejia
SYNOPSIS
Requires pharmacies to provide certain information regarding insulin manufacturer assistance programs.
CURRENT VERSION OF TEXT
Introduced Pending Technical Review by Legislative Counsel.
An Act concerning insulin manufacturer assistance programs and supplementing P.L.2003, c.280 (C.45:14-40 et seq.).
Be It Enacted by the Senate and General Assembly of the State of New Jersey:
1. a. A pharmacy practice site shall:
(1) display a notice concerning insulin manufacturer assistance programs, to be created by the Department of Banking and Insurance, at all points of sale; and
(2) provide a pamphlet concerning insulin manufacturer assistance programs, to be created by the department, to an individual purchasing a prescription for insulin and any individual requesting a pamphlet.
b. An insulin manufacturer offering an assistance program may inform the department of its intention to be included in the notices and pamphlets.
c. The department shall adopt rules and regulations pursuant to the “Administrative Procedure Act,” P.L.1968, c.410 (C.52:14B-1 et seq.), to effectuate the purposes of this act.
2. This act shall take effect on the first day of the sixth month next following the date of enactment, except that the Commissioner of Banking and Insurance may take any anticipatory administrative action in advance as shall be necessary for the implementation of this act.
STATEMENT
This bill requires pharmacies to provide certain information regarding insulin manufacturer assistance programs.
Under this bill, a pharmacy practice site will be required to display a notice, created by the Department of Banking and Insurance, concerning insulin manufacturer assistance programs at all points of sale. A pharmacy practice site will also be required to provide a pamphlet, created by the department, concerning the insulin manufacturer assistance programs to any individual purchasing a prescription for insulin, or to any individual requesting a pamphlet. Insulin manufacturers offering an assistance program may inform the department of their intention to be included in the notices and pamphlets.